China SXT Pharmaceuticals, Inc. (SXTC)

NASDAQ: SXTC · USD

$2.90

+0.02 (+0.7%)· Recorded snapshot

Market cap	38.3K
Revenue (ttm)	1.1M
Net income (ttm)	-6.2M
Shares out	13.2K
Volume	71,097.719
Beta	2.01

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.1M
Net income (ttm): -6.2M
Market cap: 38.3K

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-27.5

P25 n/aP50 n/aP75 n/a

ROIC-284.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SXTC indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001723980
Company name	China SXT Pharmaceuticals, Inc.
Country	China
Country code	US
CUSIP number	G2161P181
Earnings date	2019-08-19
Earnings time	bmo
Employees	56
Employees change	-19
Employees growth	-25.33%
Enterprise value	$-27.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-03-31
First seen	2026-05-09
Fiscal year end	March
Founded	2005
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2019-01-04
Is primary listing	Yes
Is SPAC	No
ISIN number	VGG2161P1817
Last 10-K release date	2026-07-01
Last earnings date	2019-08-19
Last refreshed	2026-11-04
Last stock split date	2026-10-26
Last stock split type	Reverse
Market cap	$38,321
Market cap category	Nano-Cap
Options	No
Price	$2.90
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-04
Symbol	SXTC
Website	https://www.sxtchina.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-16,305.14%
FCF / EV yield	14.79%
FCF yield	-10,556.7%
Industry forward P/E	14.04x
Industry P/E	107.82x
P/B ratio	0x
P/S ratio	0.03x
Price / tangible book value	0x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	21.85%
Operating margin	-625.89%
Pretax margin	-545.24%
Profit per employee	$-110,805
Revenue per employee	$20,322
ROA	-15.78%
ROA (5Y)	-9.63%
ROCE	-23.43%
ROE	-27.49%
ROE (5Y)	-29.04%
ROIC	-284.06%
SBC / revenue	466.21%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	4
Gross profit growth	-32.31%
Gross profit growth (Q)	-44.67%
Gross profit growth 3Y	-16.44%
Gross profit growth 5Y	-38.56%
Net income growth years	0
Revenue growth	-34.63%
Revenue growth (Q)	-43.88%
Revenue growth (QoQ)	-18.37%
Revenue growth 3Y	-16.74%
Revenue growth 5Y	-24.94%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$73,668
EBIT	$-7.1M
EBITDA	$-7M
FCF per share	$-304.03
Financing cash flow	$14.4M
Free cash flow	$-4M
Free cash flow minus SBC	$-9.3M
Gross profit	$248,702
Investing cash flow	$-1.3M
Net borrowing	$144,159
Net cash flow	$10M
Net income	$-6.2M
Operating cash flow minus SBC	$-9.3M
Operating income	$-7.1M
Revenue	$1.1M
Stock-based compensation	$5.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	12.18
Debt / equity	0.04
Interest coverage	-113.13
Long-term assets	$244,852
Long-term liabilities	$697,832
Net cash (debt)	$27.2M
Net cash / market cap	71,473.22%
Net cash growth	224.76%
Net debt / equity	-0.92
Piotroski F-Score	3
Property, plant and equipment	$238,524
Shareholders' equity	$29.7M
Tangible book value	$29.7M
Total assets	$34.8M
Total cash	$28.3M
Total debt	$1.1M
Total liabilities	$5M
WACC	4.79%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.04
Current assets	$34.5M
Current liabilities	$4.3M
Current ratio	7.93
Inventory turnover	0.44
Net working capital	$2.3M
Quick ratio	7.23
Working capital	$30.2M
Working capital turnover	0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$8,518.46
1D price change	0.69%
1M price change	-98.8%
1M total return	-98.8%
1W price change	-18.87%
1W total return	-18.87%
1Y price change	-100%
1Y return CAGR	-100%
1Y total return	-100%
20-day SMA	$21.37
200-day SMA	$14,331.62
3M price change	-99.42%
3M total return	-99.42%
3Y price change	-100%
3Y return CAGR	-99.48%
3Y total return	-100%
50-day SMA	$159.96
50-day SMA vs 200-day SMA	50under200
52-week high	$8,376,215.05
52-week high date	2026-01-08
52-week low	$2.71
52-week low date	2026-11-03
5Y price change	-100%
5Y return CAGR	-98.57%
5Y total return	-100%
6M price change	-99.98%
6M total return	-99.98%
After-hours change	3.13%
After-hours close	$2.88
After-hours price	$2.97
All-time high	$233,500,000,000.00
All-time high date	2019-01-10
All-time low	$2.71
All-time low date	2026-11-02
Average true range (ATR)	$50.86
Average volume	687.9K
Beta (1Y)	1.97
Beta (2Y)	0.81
Beta (5Y)	2.01
Change from 52-week high	-100%
Change from 52-week low	7.01%
Change from all-time high	-100%
Change from all-time low	6.27%
Change from open	3.57%
Day's gap	-2.78%
Dollar volume	$206,183
High price	$3.07
Low price	$2.71
Monthly RSI	19.14
Open price	$2.80
Position in 52-week range	52.78%
Premarket change	0.69%
Premarket close	$2.88
Premarket price	$2.90
Premarket volume	9.3K
Previous close	$2.88
Price vs 150-day SMA	-99.97%
Price vs 20-day SMA	-86.53%
Price vs 200-day SMA	-99.98%
Price vs 50-day SMA	-98.2%
Relative volume	0.1
Return from IPO open	-100%
Return from IPO price	-28%
RSI	27.76
Sharpe ratio	-1.98
Sharpe ratio (3Y)	-0.78
Sharpe ratio (5Y)	-0.89
Sortino ratio	-2.53
Sortino ratio (3Y)	-1.17
Sortino ratio (5Y)	-1.32
Volume	71.1K
Weekly RSI	26.34
YTD price change	-100%
YTD total return	-100%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	13.2K
Float percentage	99.73%
Shares held by insiders	0.27%
Shares held by institutions	84.23%
Shares outstanding	13.2K
Short % of shares	6.96%
Short ratio	0 days

Deeper analysis on SXTC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SXTC report

Is a complete SXTC research report available?

No complete published report is available for China SXT Pharmaceuticals, Inc. (SXTC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

China SXT Pharmaceuticals, Inc. (SXTC)

Price

Financial snapshot

Fair-value bridge

Latest news · SXTC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SXTC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SXTC

Frequently asked questions